hOX40 KI
| Status | Available to order |
| EMMA ID | EM:15705 |
| Citation information | RRID:IMSR_EM:15705 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | hOX40 KI |
| Alternative name | hOX40 KI |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Unknown at present |
| Gene/Transgene symbol | Unknown at present |
Information from provider
| Provider | Mark Cragg |
| Provider affiliation | Cancer Sceinces, University of Southampton |
| Genetic information | Gene encoding a protein expressing the human OX40 extracellular domain with mouse intracellular domain knocked into the mouse OX40 genomic locus. The coding sequences of OX40 exon 1 plus some immediate intronic sequences were replaced with a KI cassette, thus the expression of the KI cassette is under control of the mouse Tnfrsf4 gene regulatory element. To engineer the targeting vector, homology arms were generated by PCR using BAC clone RP23-139J18 from the C57BL/6J library as template. In the targeting vector, the Neo cassette was flanked by LoxP sites. |
| Phenotypic information | Homozygous:No deleterious changes. They express a receptor with human OX40 extracellular domain, that can be bound by anti-human OX40 monoclonal antibody.Heterozygous:Heterozygous mice express half as much hOX40 receptor as the homozygous mice. It also deletes one mouse allele and so expresses 50% of the mouse OX40 receptor. |
| Breeding history | Mice were generated in C57BL/6 background (ES cells). |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Literature references
- Domain binding and isotype dictate the activity of anti-human OX40 antibodies.;Griffiths Jordana, Hussain Khiyam, Smith Hannah L, Sanders Theodore, Cox Kerry L, Semmrich Monika, Mårtensson Linda, Kim Jinny, Inzhelevskaya Tatyana, Penfold Chris A, Tutt Alison L, Mockridge C Ian, Chan Ht Claude, English Vikki, French Ruth F, Teige Ingrid, Al-Shamkhani Aymen, Glennie Martin J, Frendeus Bjorn L, Willoughby Jane E, Cragg Mark S, ;2020;Journal for immunotherapy of cancer;8;; 33428585